| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 04/09/2009 | WO2009043452A1 Use of rfrp, alone or in combination with neurokinin-b, as a therapeutic agent |
| 04/09/2009 | WO2009043451A2 Use of chorionic gonadotropin-beta (109-145) as a therapeutic agent |
| 04/09/2009 | WO2009043450A2 Use of neurotrophic factor for retinal cholinergic neurons (nfrcn) and chorionic gonadotropin-beta (109-145) as therapeutic agents |
| 04/09/2009 | WO2009043449A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043448A2 Neuromedin u-25 and neuromedin s as therapeutic agents |
| 04/09/2009 | WO2009043447A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043441A1 D-ala-gln-octadecyl ester as a therapeutic agent |
| 04/09/2009 | WO2009043440A2 Use of il-1 receptor peptide, alone or in combination with d-ala-gln-octadecyl ester, as a therapeutic agent |
| 04/09/2009 | WO2009043439A2 Use of retrocyclin- 1 as a therapeutic agent for the treatment of hcmv infections |
| 04/09/2009 | WO2009043437A2 Use of t140 and optionally retrocyclin-1 as therapeutic agents for the treatment of m. tuberculosis infections |
| 04/09/2009 | WO2009043436A2 Use of af12198 as a therapeutic agent |
| 04/09/2009 | WO2009043116A1 Methods and compositions for the treatment of phosphatase- related disorders |
| 04/09/2009 | WO2009043107A1 Treatment of neurological disorders |
| 04/09/2009 | WO2009043103A1 Therapeutic antibody purification method and method of use |
| 04/09/2009 | WO2009026227A3 Highly selective sigma receptor ligands |
| 04/09/2009 | WO2009024325A3 Treatment of sleep disorders |
| 04/09/2009 | WO2009024324A3 Treatment of sleep disorders |
| 04/09/2009 | WO2009023253A3 IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO |
| 04/09/2009 | WO2009022311A3 1,2-diamido-ethylene derivatives as orexin antagonists |
| 04/09/2009 | WO2009022067A8 Medicament for treating parkinson's disease |
| 04/09/2009 | WO2009019472A4 1, 2, 4 -triazole derivatives as serotonergic modulators |
| 04/09/2009 | WO2009016384A3 Gsk-3 inhibitors |
| 04/09/2009 | WO2009003868A3 2 -imidazolines having a good affinity to the trace amine associated receptors (taars) |
| 04/09/2009 | WO2008155670A3 Arylamide pyrimidone compounds |
| 04/09/2009 | WO2008155666A3 Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases |
| 04/09/2009 | WO2008155534A3 Neurosteroid compounds |
| 04/09/2009 | WO2008151841A3 Treatment for alzheimer' s disease |
| 04/09/2009 | WO2008148879A3 Use of a substance to improve postoperative outcome after end-to-end reconstruction of peripheral nerves |
| 04/09/2009 | WO2008138943A3 Prophylactic and therapeutic use of sirtuin inhibitors in tnf-alpha mediated pathologies |
| 04/09/2009 | WO2008122667A3 Ureylene derivatives |
| 04/09/2009 | WO2006014703A3 Homopiperdinine derivatives as nk-1 antagonists |
| 04/09/2009 | WO2002026020A9 Tricyclic antidepressants and their analogues as long-acting local anesthetics and analgesics |
| 04/09/2009 | US20090093639 Prodrugs of carbamate inhibitors of IMPDH |
| 04/09/2009 | US20090093534 Mu opioid receptor ligands: methods of use and synthesis |
| 04/09/2009 | US20090093521 2, 5-Bis-Diamine [1,4] Benzoquinone-Derivatives |
| 04/09/2009 | US20090093518 Piperidinyl-substituted isoquinolone derivatives |
| 04/09/2009 | US20090093517 Bis1,2,3,4-tetrahydroisoquinoline derivatives and their uses as pharmaceuticals |
| 04/09/2009 | US20090093513 Method to Use Compositions Having Antidepressant Anxiolytic and Other Neurological Activity and Compositions of Matter |
| 04/09/2009 | US20090093512 1, 2, 3, 3a, 8, 8a-hexahydro-2, 7a-diada-cyclopenta[a]inden-7-one derivatives which bind to neuronal nicotinic acetylcholine specific receptor sites and are useful in modulating cholinergic function and in the treatment of addictive disorders |
| 04/09/2009 | US20090093498 And beta-amyloid formation; Alzheimer's Disease; 2-amino-5-(4-fluoro-3-pyrimidin-5-ylphenyl)-5-(4-methoxy-3-methylphenyl)-3-methyl-3,5-dihydro-4H-imidazol-4-one |
| 04/09/2009 | US20090093478 N-aroyl cyclic amines |
| 04/09/2009 | US20090093471 Methods of Treating Nervous Disorders |
| 04/09/2009 | US20090093469 Phenylaminopropanol Derivatives and Methods of Their Use |
| 04/09/2009 | US20090093464 Naphthalene Derivatives as Modulators of the Glucocorticoid Receptor |
| 04/09/2009 | US20090093462 3-Arylamino pyridine derivatives |
| 04/09/2009 | US20090093461 Methods of Treating Anxiety and Mood Disorders |
| 04/09/2009 | US20090093453 Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof |
| 04/09/2009 | US20090093451 IL-8 Receptor Antagonists |
| 04/09/2009 | US20090093433 SENSE mRNA THERAPY |
| 04/09/2009 | US20090093409 Neuroprotective synergy of erythropoietin and insulin-like growth factors |
| 04/09/2009 | US20090093403 Systems, methods and compositions for optical stimulation of target cells |
| 04/09/2009 | US20090093000 Glycoprotein and apolipoprotein biopolymer markers predictive of Alzheimers disease |
| 04/09/2009 | US20090092672 Orally disintegrating tablet compositions of lamotrigine |
| 04/09/2009 | US20090092671 Cerium Oxide Nanoparticles for Treatment and Prevention of Alzheimer's Disease, Parkinson's Disease, and Disorders Associated with Free Radical Production and/or Mitochondrial Dysfunction |
| 04/09/2009 | US20090092668 Acetaminophen formulation for joint pain relief |
| 04/09/2009 | US20090092667 Method for Reducing Amyloid Deposition, Amyloid Neurotoxicity, and Microgliosis with (-)-Nilvadipine Enantiomer |
| 04/09/2009 | US20090092611 Antibodies that bind both bcma and taci |
| 04/09/2009 | US20090092605 Compositions and methods for the treatment of immune related diseases |
| 04/09/2009 | US20090092604 Method for the Treatment of Multiple Sclerosis by Inhibiting IL-17 Activity |
| 04/09/2009 | US20090092579 Novel method for down-regulation of amyloid |
| 04/09/2009 | US20090092573 Method of manufacturing a nicotine delivery product |
| 04/09/2009 | US20090092545 Antibodies that bind both bcma and taci |
| 04/09/2009 | DE19681421B4 Vorrichtung und Bereitstellungsverfahren für eine transdermale Elektrotransport-Abgabe von Fentanyl und Sufentanil Apparatus and method for providing a transdermal electrotransport delivery of fentanyl and sufentanil |
| 04/09/2009 | DE19543553B4 VP-Antigene des JC-Virus VP-antigens of the JC virus |
| 04/09/2009 | CA2710406A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2701846A1 Extracellular targets for alzheimer's disease |
| 04/09/2009 | CA2701778A1 Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
| 04/09/2009 | CA2701620A1 Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer |
| 04/09/2009 | CA2701618A1 Pharmaceutical composition for inhibiting amyloid-beta protein accumulation |
| 04/09/2009 | CA2701577A1 Treatment of neurological disorders |
| 04/09/2009 | CA2701414A1 Process for the preparation of zolmitriptan, salts and solvates thereof |
| 04/09/2009 | CA2701406A1 Benzoxazinone derivative |
| 04/09/2009 | CA2701397A1 Nerve cell death inhibitor |
| 04/09/2009 | CA2701214A1 Tetrazole-substituted aryl amide derivatives and uses thereof |
| 04/09/2009 | CA2701203A1 N-substituted oxindoline derivatives as calcium channel blockers |
| 04/09/2009 | CA2701179A1 Compositions and methods for enhancing cognitive function |
| 04/09/2009 | CA2701172A1 Methods of treating neurological autoimmune disorders with cyclophosphamide |
| 04/09/2009 | CA2701128A1 Antisense modulation of fibroblast growth factor receptor 4 expression |
| 04/09/2009 | CA2701126A1 Quinuclidin-4-ylmethyl 1h-indole-3-carboxylate derivatives as alpha 7 nicotinic acetylcholine receptor ligands for the treatment of alzheimer's disease |
| 04/09/2009 | CA2701075A1 Therapeutic use of diaminophenothiazines |
| 04/09/2009 | CA2700964A1 Gamma secretase modulators |
| 04/09/2009 | CA2700963A1 Oxypiperidine derivatives and methods of use thereof |
| 04/09/2009 | CA2700928A1 Novel compounds |
| 04/09/2009 | CA2700762A1 Pyridine derivatives for the treatment of amyloid-related diseases |
| 04/09/2009 | CA2700724A1 Modulators of muscarinic receptors |
| 04/09/2009 | CA2699625A1 Cyclopropyl aryl amide derivatives and uses thereof |
| 04/09/2009 | CA2699264A1 Substance p and thyrotropin releasing hormone for therapeutic applications |
| 04/09/2009 | CA2699260A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2699255A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2699138A1 Compounds and methods for pharmaceutical use |
| 04/09/2009 | CA2699114A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2699113A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2699109A1 Use of urocortin and corticotropin-releasing factor as therapeutic agents |
| 04/09/2009 | CA2699107A1 Use of a platelet fibrinogen receptor hexapeptide antagonist and alpha-endorphin as therapeutic agents |
| 04/09/2009 | CA2699105A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2699104A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2699078A1 Use of grf-1 (1-29 ) and corticotropin-releasing factor as therapeutic agents |
| 04/09/2009 | CA2699074A1 Use of a peptide as a therapeutic agent |
| 04/09/2009 | CA2699067A1 Use of rfrp, alone or in combination with neurokinin-b, as a therapeutic agent |
| 04/09/2009 | CA2698690A1 Thyrotropin releasing hormone for therapeutic applications |